Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, is a nurse practitioner at University of California San Diego Health.
CDK4/6 Inhibition Customizes Frontline HR+, HER2- mBC Treatment
According to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, the availability of 3 CDK4/6 inhibitors in first-line mBC therapy gives patients more choices.
How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC
The number of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC